[artículo] 
inJournal of Clinical Psychopharmacology > Año 2000 - Vol. 20 - No. 2 (Abril) . - pp. 181-187

Título :	Pharmacologic profile of perphenazine's metabolites
Tipo de documento:	texto impreso
Autores:	Robert A. Sweet, Autor ; Bruce G. Pollock, Autor ; Benoit H. Mulsant, Autor
Fecha de publicación:	2023
Artículo en la página:	pp. 181-187
Idioma :	Inglés (eng) Idioma original : Inglés (eng)
Palabras clave:	Antipsicóticos, Efectos cerebrales, Demencia, Antagonistas de la dopamina, Perfenazina.
Resumen:	The authors have previously reported that in elderly patients treated with low doses of perphenazine, few extrapyramidal symptoms (EPS) developed in those who were not poor CYP2D6 metabolizers. The authors hypothesized that this atypical side effect profile is due to perphenazine's principal metabolite, n-dealkylperphenazine (DAPZ), which is usually present in vivo at concentrations 1.5 to 2 times that of the parent drug.
Link:	./index.php?lvl=notice_display&id=31213

[artículo] Pharmacologic profile of perphenazine's metabolites [texto impreso] / Robert A. Sweet, Autor ; Bruce G. Pollock, Autor ; Benoit H. Mulsant, Autor . - 2023 . - pp. 181-187.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in Journal of Clinical Psychopharmacology > Año 2000 - Vol. 20 - No. 2 (Abril) . - pp. 181-187

Palabras clave:	Antipsicóticos, Efectos cerebrales, Demencia, Antagonistas de la dopamina, Perfenazina.
Resumen:	The authors have previously reported that in elderly patients treated with low doses of perphenazine, few extrapyramidal symptoms (EPS) developed in those who were not poor CYP2D6 metabolizers. The authors hypothesized that this atypical side effect profile is due to perphenazine's principal metabolite, n-dealkylperphenazine (DAPZ), which is usually present in vivo at concentrations 1.5 to 2 times that of the parent drug.
Link:	./index.php?lvl=notice_display&id=31213